Cytomegalovirus Colitis Following Azacitidine Therapy | Zendy

Rajal Khan | Zendy; Pam Rudkin | Zendy; Kuljit Grewal | Zendy; Jennifer Leonard | Zendy; Mowafak Hamodat | Zendy; Jim Hutchinson | Zendy; Peter Daley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cytomegalovirus Colitis Following Azacitidine Therapy

Author(s) -

Rajal Khan,

Pam Rudkin,

Kuljit Grewal,

Jennifer Leonard,

Mowafak Hamodat,

Jim Hutchinson,

Peter Daley

Publication year - 2011

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2011/616725

Subject(s) - azacitidine , medicine , cytomegalovirus , colitis , ganciclovir , cytomegalovirus infection , cytomegalovirus infections , immunology , intensive care medicine , gastroenterology , oncology , herpesviridae , virus , human cytomegalovirus , viral disease , biology , gene , dna methylation , biochemistry , gene expression

The present report describes the first recognized case of cytomegalovirus (CMV) colitis following azacitidine therapy. A 66-year-old woman with myelodysplastic syndrome developed CMV colitis, which responded to treatment with ganciclovir. Currently, patients receiving azacitidine do not undergo CMV testing, or receive prophylaxis or CMV-free blood products; however, this policy needs to be revised.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research